Tango Therapeutics, Inc. TNGX
24.30 USD +1.56 (+6.86%)
At closeNov 10, 2026, 4:52 PM EST
24.30 0.00 0.00%
After hours · Nov 10, 4:52 PM ET
22.38 Day range 24.65
7.49 52-week range 34.39
- YTD
- +174.27%
- 1 year
- +206.43%
- Market cap
- 4.12B
- EPS (ttm)
- -1.47
- Shares out
- 169.46M
- Forward P/E
- -13.48
- YTD return
- +174.27%
- 1-year return
- +206.43%
- Volume
- 4.56M
- Avg volume
- 3.33M
- Open
- 22.74
- Previous close
- 22.74
- Day's range
- 22.38 – 24.65
- 52-week range
- 7.49 – 34.39
- Beta
- 1.22
- Analysts
- Strong Buy
- Price target
- 46.64 (+91.9%)
- Earnings date
- Mar 29, 2027
5D +0.33 (+1.38%)
Key statistics
- Enterprise value
- 2.91B
- PEG ratio
- 0.00
- Price / book
- 4.19
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -80.18M
- Total cash
- 977.50M
- Total debt
- 31.18M
- Return on equity
- -36.48%
- Short % of float
- 26.76%
- 50-day average
- 23.32
- 200-day average
- 22.63
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 46.64 +91.9% upside
Now 24.30
- Target (low)
- 24.00
- Target (mean)
- 46.64
- Target (high)
- 69.00
Ratings (0m) 13 12 buy · 1 hold · 0 sell
- Strong buy1
- Buy11
- Hold1
- Sell0
- Strong sell0
Next earnings
Mar 29, 2027
Expected Mar 29, 2027. Consensus EPS estimate -0.39231.
Financials — quick view
TNGX Revenue — quarterly 0
TNGX Net income — quarterly -68.39M
TNGX EPS — quarterly -0.39
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 29, 2027 | Mar 30, 2027 | -0.37953 | — | — | — |
| Nov 9, 2026 | Sep 30, 2026 | -0.35297 | -0.39 | -0.04 | -10.49% |
| Aug 10, 2026 | Jun 30, 2026 | -0.31722 | -0.37 | -0.05 | -16.64% |
| May 13, 2026 | Mar 31, 2026 | -0.3137 | -0.32 | -0.01 | -2.01% |
| Mar 5, 2026 | Dec 31, 2025 | -0.31 | -0.29 | +0.02 | +6.45% |
| Nov 4, 2025 | Sep 30, 2025 | 0.01 | 0.13 | +0.12 | +1,200.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 10, 2026 | JP Morgan | main | Overweight | Overweight |
| Nov 10, 2026 | Wedbush | main | Outperform | Outperform |
| Nov 10, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Oct 29, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 16, 2026 | William Blair | init | — | Outperform |
| Aug 18, 2026 | HC Wainwright & Co. | main | Buy | Buy |
About Tango Therapeutics, Inc.
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- tangotx.com
News
JP Morgan Maintains Overweight on Tango Therapeutics, Raises Price Target to $47 
Wedbush Maintains Outperform on Tango Therapeutics, Lowers Price Target to $40 
HC Wainwright & Co. Maintains Buy on Tango Therapeutics, Lowers Price Target to $67 
Tango Therapeutics Q3 EPS $(0.39) Misses $(0.35) Estimate 
Tango Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights 
Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015 
Tango Therapeutics to Participate in Guggenheim's 3rd Annual Healthcare Innovation Conference 
Tango: Upgrading 'Buy' Based On ESMO 2026 Vopimetostat PDAC Data And Pathway Advancement Clarity - HC Wainwright & Co. Reiterates Buy on Tango Therapeutics, Maintains $68 Price Target
Tango Therapeutics: The ESMO Sell-Off Missed What The Daraxonrasib Dose Is Saying
Your note
Sign in to keep a note on TNGX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARRY DOUGLAS | General Counsel | Sale | Feb 4, 2025 | 66,014 |
| BECKMAN DANIELLA | Chief Financial Officer | Sale | Feb 2, 2026 | 184,297 |
| CRYSTAL ADAM S | Officer | Sale | Nov 1, 2026 | 115,743 |
| GALL MATTHEW | Chief Financial Officer | Stock Award(Grant) | Apr 30, 2026 | 40,000 |
| KETCHUM JOHN B | Director | Stock Award(Grant) | Jun 4, 2026 | 24,937 |
| NEWCOMB JESSICA | Officer | Sale | Nov 1, 2026 | 52,090 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RTW Investments LP | 8.24% | 13,900,620 | 337.79M | Jun 29, 2026 |
| Blackrock Inc. | 7.38% | 12,438,444 | 302.25M | Jun 29, 2026 |
| FMR, LLC | 7.31% | 12,333,339 | 299.70M | Jun 29, 2026 |
| Farallon Capital Management LLC | 7.28% | 12,277,000 | 298.33M | Jun 29, 2026 |
| Boxer Capital Management, LLC | 6.45% | 10,876,219 | 264.29M | Jun 29, 2026 |
| Goldman Sachs Group Inc | 5.92% | 9,980,620 | 242.53M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.61% | 4,395,732 | 106.82M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.41% | 4,065,305 | 98.79M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.16% | 3,649,644 | 88.69M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1.67% | 2,818,158 | 68.48M | Sep 29, 2026 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 1.67% | 2,816,262 | 68.44M | Sep 29, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 0.92% | 1,546,027 | 37.57M | Jun 29, 2026 |